FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034161863> ?p ?o ?g. }

• W2034161863 endingPage "798" @default.
• W2034161863 startingPage "793" @default.
• W2034161863 abstract "Background Psoralen plus ultraviolet A (PUVA) for the treatment of psoriasis has never been evaluated using the Psoriasis Area Severity Index (PASI) in a randomized, double-blind, placebo-controlled trial. The lack of such data limits our capacity to estimate PUVA's efficacy relative to other treatment options that are available today. Objectives The purpose of this study was to evaluate the efficacy of PUVA therapy for patients with plaque-type psoriasis. Methods This study involved 40 patients with psoriasis; 30 received PUVA and 10 received UVA with placebo. PASI scores were assessed at baseline and every 4 weeks thereafter for 12 weeks. Results By nonresponder imputation, 60% (18 of 30) in the PUVA group achieved 75% or more improvement in PASI score after 12 weeks of treatment compared with 0% (0 of 10) in the UVA plus placebo group (P < .0001). Using intent to treat with last observation carried forward analysis, 63% (19 of 30) in the PUVA group achieved 75% or more improvement in PASI score compared with 0% (0 of 10) in the UVA plus placebo group (P < .0001). By per protocol analysis, 86% (18 of 21) in the PUVA group as compared with 0% (0 of 7) in the UVA plus placebo group reached 75% or more improvement in PASI score after 12 weeks (P < .0001). Limitations The study was relatively small with only 40 patients enrolled and 28 patients who completed the protocol. Further studies that involve head-to-head comparison of PUVA with other treatment modalities are needed. Nonresponder imputation, last observation carried forward with intent to treat, and per protocol analyses each have separate advantages and limitations when determining clinical significance. Conclusions This study supports the observation that PUVA is a highly efficacious treatment for chronic plaque psoriasis. Psoralen plus ultraviolet A (PUVA) for the treatment of psoriasis has never been evaluated using the Psoriasis Area Severity Index (PASI) in a randomized, double-blind, placebo-controlled trial. The lack of such data limits our capacity to estimate PUVA's efficacy relative to other treatment options that are available today. The purpose of this study was to evaluate the efficacy of PUVA therapy for patients with plaque-type psoriasis. This study involved 40 patients with psoriasis; 30 received PUVA and 10 received UVA with placebo. PASI scores were assessed at baseline and every 4 weeks thereafter for 12 weeks. By nonresponder imputation, 60% (18 of 30) in the PUVA group achieved 75% or more improvement in PASI score after 12 weeks of treatment compared with 0% (0 of 10) in the UVA plus placebo group (P < .0001). Using intent to treat with last observation carried forward analysis, 63% (19 of 30) in the PUVA group achieved 75% or more improvement in PASI score compared with 0% (0 of 10) in the UVA plus placebo group (P < .0001). By per protocol analysis, 86% (18 of 21) in the PUVA group as compared with 0% (0 of 7) in the UVA plus placebo group reached 75% or more improvement in PASI score after 12 weeks (P < .0001). The study was relatively small with only 40 patients enrolled and 28 patients who completed the protocol. Further studies that involve head-to-head comparison of PUVA with other treatment modalities are needed. Nonresponder imputation, last observation carried forward with intent to treat, and per protocol analyses each have separate advantages and limitations when determining clinical significance. This study supports the observation that PUVA is a highly efficacious treatment for chronic plaque psoriasis." @default.
• W2034161863 created "2016-06-24" @default.
• W2034161863 creator A5000362885 @default.
• W2034161863 creator A5003620848 @default.
• W2034161863 creator A5009204818 @default.
• W2034161863 creator A5018239511 @default.
• W2034161863 creator A5027597877 @default.
• W2034161863 creator A5031205710 @default.
• W2034161863 creator A5035757309 @default.
• W2034161863 creator A5043704722 @default.
• W2034161863 date "2009-11-01" @default.
• W2034161863 modified "2023-10-14" @default.
• W2034161863 title "Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks" @default.
• W2034161863 cites W1973443311 @default.
• W2034161863 cites W2018556584 @default.
• W2034161863 cites W2030796649 @default.
• W2034161863 cites W2045813582 @default.
• W2034161863 cites W2051640398 @default.
• W2034161863 cites W2052364506 @default.
• W2034161863 cites W2054678820 @default.
• W2034161863 cites W2062524492 @default.
• W2034161863 cites W2068652930 @default.
• W2034161863 cites W2083778751 @default.
• W2034161863 cites W2172257129 @default.
• W2034161863 cites W2336000290 @default.
• W2034161863 cites W4232818232 @default.
• W2034161863 cites W4238943324 @default.
• W2034161863 doi "https://doi.org/10.1016/j.jaad.2009.04.053" @default.
• W2034161863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19766350" @default.
• W2034161863 hasPublicationYear "2009" @default.
• W2034161863 type Work @default.
• W2034161863 sameAs 2034161863 @default.
• W2034161863 citedByCount "31" @default.
• W2034161863 countsByYear W20341618632012 @default.
• W2034161863 countsByYear W20341618632013 @default.
• W2034161863 countsByYear W20341618632014 @default.
• W2034161863 countsByYear W20341618632015 @default.
• W2034161863 countsByYear W20341618632016 @default.
• W2034161863 countsByYear W20341618632017 @default.
• W2034161863 countsByYear W20341618632018 @default.
• W2034161863 countsByYear W20341618632019 @default.
• W2034161863 countsByYear W20341618632020 @default.
• W2034161863 countsByYear W20341618632021 @default.
• W2034161863 countsByYear W20341618632023 @default.
• W2034161863 crossrefType "journal-article" @default.
• W2034161863 hasAuthorship W2034161863A5000362885 @default.
• W2034161863 hasAuthorship W2034161863A5003620848 @default.
• W2034161863 hasAuthorship W2034161863A5009204818 @default.
• W2034161863 hasAuthorship W2034161863A5018239511 @default.
• W2034161863 hasAuthorship W2034161863A5027597877 @default.
• W2034161863 hasAuthorship W2034161863A5031205710 @default.
• W2034161863 hasAuthorship W2034161863A5035757309 @default.
• W2034161863 hasAuthorship W2034161863A5043704722 @default.
• W2034161863 hasConcept C126322002 @default.
• W2034161863 hasConcept C142724271 @default.
• W2034161863 hasConcept C16005928 @default.
• W2034161863 hasConcept C168563851 @default.
• W2034161863 hasConcept C204787440 @default.
• W2034161863 hasConcept C27081682 @default.
• W2034161863 hasConcept C2777011040 @default.
• W2034161863 hasConcept C2780200183 @default.
• W2034161863 hasConcept C2780564577 @default.
• W2034161863 hasConcept C2781110370 @default.
• W2034161863 hasConcept C30036603 @default.
• W2034161863 hasConcept C54355233 @default.
• W2034161863 hasConcept C552990157 @default.
• W2034161863 hasConcept C71924100 @default.
• W2034161863 hasConcept C86803240 @default.
• W2034161863 hasConceptScore W2034161863C126322002 @default.
• W2034161863 hasConceptScore W2034161863C142724271 @default.
• W2034161863 hasConceptScore W2034161863C16005928 @default.
• W2034161863 hasConceptScore W2034161863C168563851 @default.
• W2034161863 hasConceptScore W2034161863C204787440 @default.
• W2034161863 hasConceptScore W2034161863C27081682 @default.
• W2034161863 hasConceptScore W2034161863C2777011040 @default.
• W2034161863 hasConceptScore W2034161863C2780200183 @default.
• W2034161863 hasConceptScore W2034161863C2780564577 @default.
• W2034161863 hasConceptScore W2034161863C2781110370 @default.
• W2034161863 hasConceptScore W2034161863C30036603 @default.
• W2034161863 hasConceptScore W2034161863C54355233 @default.
• W2034161863 hasConceptScore W2034161863C552990157 @default.
• W2034161863 hasConceptScore W2034161863C71924100 @default.
• W2034161863 hasConceptScore W2034161863C86803240 @default.
• W2034161863 hasIssue "5" @default.
• W2034161863 hasLocation W20341618631 @default.
• W2034161863 hasLocation W20341618632 @default.
• W2034161863 hasOpenAccess W2034161863 @default.
• W2034161863 hasPrimaryLocation W20341618631 @default.
• W2034161863 hasRelatedWork W1968892760 @default.
• W2034161863 hasRelatedWork W2006760364 @default.
• W2034161863 hasRelatedWork W2041051947 @default.
• W2034161863 hasRelatedWork W2042893181 @default.
• W2034161863 hasRelatedWork W2060142842 @default.
• W2034161863 hasRelatedWork W2588369178 @default.
• W2034161863 hasRelatedWork W2781166685 @default.
• W2034161863 hasRelatedWork W3022724713 @default.
• W2034161863 hasRelatedWork W3027135752 @default.
• W2034161863 hasRelatedWork W4320521215 @default.

• next